Bristol-Myers Squibb Co (NYSE:BMY) Investor Investigation Concerning Possible Breaches Of Fiduciary Duties Announced

If you purchased shares of Bristol-Myers Squibb Co (NYSE:BMY) and currently hold any of those NYSE:BMY shares, you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Bristol-Myers Squibb Co.
Affected Securities: 
NYSE: BMY

August 23, 2016 (Shareholders Foundation) - An investigation on behalf of current long-term investors in shares of Bristol-Myers Squibb Co (NYSE:BMY) was announced over potential breaches of fiduciary duties by certain officers and directors at Bristol-Myers Squibb.

The investigation by a law firm concerns whether certain Bristol-Myers Squibb Co officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

In October 2015, Bristol-Myers Squibb Co reached a civil settlement with the Securities and exchange Commission (“SEC”) of alleged Foreign Corrupt Practices Act (FCPA) violations in which the Company agreed to approximately $14.7 million in disgorgement, penalties and interest.
Bristol-Myers Squibb Co reported that its annual Total Revenue rose from over $15.87 billion in 2014 to over $16.56 billion in 2015 while its Net Income declined from over $2 billion in 2014 to over $1.56 billion in 2015.

Shares of Bristol-Myers Squibb Co (NYSE:BMY) declined from $76.30 per share on August 1, 2016 to as low as $58.07 per share on August 17, 2016.